Curriculum Vitae

Personal information

Christophe Van Dijck

Work experience

4/2019 - present; specialist in internal medicine; Institute of Tropical Medicine Antwerp, Belgium; infectious disease consultant outpatient clinic

01/2023 - present; postdoctoral researcher; Research Foundation Flanders (FWO) Belgium; academic research

01/2023 - present; postdoctoral researcher; Institute of Tropical Medicine Antwerp; academic research

01/2023 - present; postdoctoral researcher; Catholic University Leuven (KUL); academic research

01/2023 - present; postdoctoral researcher; Hasselt University, Belgium; academic research

04/2019 - 12/2022; predoctoral researcher; Institute of Tropical Medicine Antwerp, Belgium; academic research

04/2018 - 02/2019; resident in internal medicine; Antwerp University Hospital, Belgium; clinical specialty training

10/2017 - 03/2018 ; resident in internal medicine; Leuven University Hospital, Belgium; clinical specialty training

04/2016 - 09/2017 ; resident in internal medicine; Antwerp University Hospital, Belgium; clinical specialty training

08/2014 - 07/2015 ; resident in internal medicine; Hospital GZA St. Vincentius, Antwerp, Belgium; clinical specialty training

08/2013 - 07/2014 ; resident in internal medicine; Hospital AZ Nikolaas, Sint-Niklaas, Belgium; clinical specialty training

Education and training

2019 - 2022 phd in medical sciences

University of Antwerp & Institute of Tropical Medicine Antwerp, Belgium

Title: "Antimicrobial resistance in Neisseria gonorrhoeae"

2018 - 2021 Certificate interuniversitaire en infectiologie et microbiologie clinique

Interuniversity training, Belgium

Université Libre de Bruxelles, Université Catholique de Louvain, Université de Liège

2018 – 2019 bijzondere opleiding antibioticabeleid

Interuniversity training, Belgium

Universiteit Leuven, Universiteit Antwerpen, Universiteit Gent

2013 - 2019 Master of specialist medicine – internal medicine

University of Antwerp, Belgium

2015 - 2016 Postgraduate certificate in tropical medicine & international health

Institute of Tropical Medicine Antwerp, Belgium

2009 - 2013 Master of medicine

University of Antwerp, Belgium

2006 - 2009 Bachelor of medicine, University of Antwerp, Belgium

Additional information

Publications

1
Visentin A, Nazeri A, Peñalvo JL, et al. Lessons from the European mpox outbreak: strengthening cohort research for future pandemic preparedness. Clin Microbiol Infect 2026; 32: 62–9.
2
Kremer C, Nundu SS, Vakaniaki EH, et al. Epidemiological characteristics of monkeypox virus Clade Ib in the Democratic Republic of the Congo. Nat Commun 2025; 17: 180.
3
Van Dijck C, Berens-Riha N, Zaeck LM, et al. Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study. Lancet Infect Dis 2025; : S1473-3099(25)00545-6.
4
De Baetselier I, Coppens J, Van Dijck C, et al. PP04.43 - Results of a Pooled Screening Method to Monitor Mpox Circulation Among Men Who Have Sex with Men Attending a Sexual Health Service to Test for Chlamydia/Gonorrhea

in Belgium, 2023-2024. Sex Health 2025; 22: SHv22n4abs.
5
Vakaniaki EH, Kuispond N-RS, Hirata Y, et al. Three Cases of Vertical Transmission of Clade Ib Mpox Virus. N Engl J Med 2025; 392: 2385–7.
6
Tsoumanis A, Vanbaelen T, Van Dijck C, Kenyon C, Hens N. Screening for gonorrhoea and chlamydia: identifying key target populations and intensity-a modelling study of MSM in Belgium. Sex Transm Infect 2025; : sextrans-2025-056540.
7
Tsoumanis A, Van Dijck C, Hens N, Kenyon C. Switching From Dual to Monotherapy for Gonorrhea is Associated With a Halving of Gonococcal Resistance to Azithromycin-A Modelling Study of MSM in Belgium. Open Forum Infect Dis 2025; 12: ofaf320.
8
Bangwen E, Berens-Riha N, de Vrij N, et al. No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients. J Med Virol 2025; 97: e70320.
9
Brosius I, Vakaniaki EH, Mukari G, et al. Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study. Lancet 2025; 405: 547–59.
10
Bangwen E, Diavita R, De Vos E, et al. Suspected and confirmed mpox cases in DR Congo: a retrospective analysis of national epidemiological and laboratory surveillance data, 2010-23. Lancet 2025; 405: 408–19.
11
Hens M, Declercq S, Berens-Riha N, et al. Rabies post-exposure prophylaxis: A retrospective analysis of timing of initiation and antibody responses in a Belgian cohort. Travel Med Infect Dis 2024; 62: 102761.
12
De Vos E, Van Gestel L, Brosius I, et al. Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study. Int J Infect Dis 2024; 146: 107132.
13
de Block T, De Baetselier I, Van den Bossche D, et al. Genomic oropharyngeal Neisseria surveillance detects MALDI-TOF MS species misidentifications and reveals a novel Neisseria cinerea clade. J Med Microbiol 2024; 73. DOI:10.1099/jmm.0.001871.
14
Tsoumanis A, Vanden Berghe W, Hens N, Van Dijck C. Estimating Partnership Duration among MSM in Belgium-A Modeling Study. Infect Dis Rep 2024; 16: 435–47.
15
Vanbaelen T, Tsoumanis A, Florence E, et al. Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial. Lancet HIV 2024; 11: e233–44.
16
Van Dijck C, Crozier I, Vercauteren K, et al. Beware of drug resistance: Let's not lose tecovirimat against mpox. Clin Microbiol Infect 2024; 30: 276–8.
17
Vanbaelen T, Laumen J, Van Dijck C, De Block T, Manoharan-Basil SS, Kenyon C. Lack of Association between Antimicrobial Consumption and Antimicrobial Resistance in a HIV Preexposure Prophylaxis Population: A Cross-Sectional Study. Antibiotics (Basel) 2024; 13. DOI:10.3390/antibiotics13020188.
18
Liesenborghs L, Coppens J, Van Dijck C, et al. No Evidence for Clade I Monkeypox Virus Circulation, Belgium. Emerg Infect Dis 2024; 30: 402.
19
Abdellati S, Laumen JGE, de Block T, et al. Gonococcal resistance to zoliflodacin could emerge via transformation from commensal Neisseria species. An in-vitro transformation study. Sci Rep 2024; 14: 1179.
20
Abdellati S, Gestels Z, Laumen JGE, et al. Antimicrobial susceptibility of commensal Neisseria spp. in parents and their children in Belgium: a cross-sectional survey. FEMS Microbiol Lett 2024; 371: fnae069.
21
Coppens J, Liesenborghs L, Vercauteren K, Van Esbroeck M, Van Dijck C. No Varicella Zoster Virus Infection among Mpox Cases in Antwerp, Belgium. Am J Trop Med Hyg 2023; 109: 1282–3.
22
Van Dijck C, Hoff NA, Mbala-Kingebeni P, et al. Emergence of mpox in the post-smallpox era-a narrative review on mpox epidemiology. Clin Microbiol Infect 2023; 29: 1487–92.
23
Vanbaelen T, Florence E, Van Dijck C, et al. Effect on the resistome of dual- vs monotherapy for the treatment of Neisseria gonorrhoeae: results from a randomized controlled trial (ResistAZM Trial). Open Forum Infectious Diseases 2023; : ofad462.
24
Mertes H, Rezende AM, Brosius I, et al. Tecovirimat Resistance in an Immunocompromised Patient With Mpox and Prolonged Viral Shedding. Ann Intern Med 2023; 176: 1141–3.
25
Van Dijck C, Kenyon C. No evidence of reduced cephalosporin susceptibility of circulating strains of Neisseria gonorrhoeae in the Netherlands despite nearly a decade of recommending ceftriaxone monotherapy. Sex Transm Infect 2023; 99: 213–4.
26
Brosius I, Van Dijck C, Coppens J, et al. Presymptomatic viral shedding in high-risk mpox contacts: A prospective cohort study. J Med Virol 2023; 95: e28769.
27
Van Dijck C, Laumen JGE, de Block T, et al. The oropharynx of men using HIV pre-exposure prophylaxis is enriched with antibiotic resistance genes: A cross-sectional observational metagenomic study. J Infect 2023; 86: 329–37.
28
Tsoumanis A, Van Dijck C, Hens N, Kenyon C. Rethinking Screening Intensity in Terms of Reducing Prevalence or Increasing Selection Pressure for the Emergence of Resistant Gonorrhea: A Modeling Study of Men Who Have Sex With Men in Belgium. Open Forum Infect Dis 2023; 10: ofad165.
29
Liesenborghs L, Huyst V, Van Dijck C, et al. Urethritis Without Skin Lesions as the Primary Manifestation of Mpox Virus Infection. Eur Urol 2023; 83: 378–9.
30
Van Dijck C, De Baetselier I, Kenyon C, Liesenborghs L, Vercauteren K, Van Esbroeck M. Mpox screening in high-risk populations finds no asymptomatic cases. Lancet Microbe 2023; 4: e132–3.
31
Hens M, Brosius I, Berens-Riha N, et al. Characteristics of confirmed mpox cases among clinical suspects: A prospective single-centre study in Belgium during the 2022 outbreak. New Microbes New Infect 2023; 52: 101093.
32
Van Dijck C, Hens N, Kenyon C, Tsoumanis A. The Roles of Unrecognized Mpox Cases, Contact Isolation and Vaccination in Determining Epidemic Size in Belgium: A Modeling Study. Clin Infect Dis 2023; 76: e1421–3.
33
Berens-Riha N, Bracke S, Rutgers J, et al. Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022. Euro Surveill 2023; 28. DOI:10.2807/1560-7917.ES.2023.28.7.2300072.

34
Postovskaya A, Vujkovic A, de Block T, et al. Leveraging T-cell receptor - epitope recognition models to disentangle unique and cross-reactive T-cell response to SARS-CoV-2 during COVID-19 progression/resolution. Front Immunol 2023; 14: 1130876.
35
Bangwen E, Diavita R, De Vos E, et al. The evolving epidemiology and ecology of mpox in Maniema, Democratic Republic of the Congo: Findings from a decade of surveillance data. Tropical Medicine & International Health 2023; 28: 233–4.
36
Akomoneh EA, Laumen JGE, Abdellati S, et al. The Discovery of Oropharyngeal Microbiota with Inhibitory Activity against Pathogenic Neisseria gonorrhoeae and Neisseria meningitidis: An In Vitro Study of Clinical Isolates. Microorganisms 2022; 10. DOI:10.3390/microorganisms10122497.
37
De Baetselier I, Van Dijck C, Kenyon C, et al. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. Nat Med 2022; 28: 2288–92.
38
González N, Abdellati S, De Baetselier I, et al. Ciprofloxacin Concentrations 1/1000th the MIC Can Select for Antimicrobial Resistance in N. gonorrhoeae-Important Implications for Maximum Residue Limits in Food. Antibiotics (Basel) 2022; 11. DOI:10.3390/antibiotics11101430.
39
González N, Abdellati S, De Baetselier I, et al. Alternative Pathways to Ciprofloxacin Resistance in Neisseria gonorrhoeae: An In Vitro Study of the WHO-P and WHO-F Reference Strains. Antibiotics (Basel) 2022; 11. DOI:10.3390/antibiotics11040499.
40
Vanbaelen T, Van Dijck C, Laumen J, et al. Global epidemiology of antimicrobial resistance in commensal Neisseria species: A systematic review. Int J Med Microbiol 2022; 312: 151551.
41
Dijck CV, Laumen J, Abdellati S, Baetselier ID, Martiny D, Kenyon C. Low Macrolide and Fluoroquinolone Susceptibility in Non-pathogenic Neisseriae in the General Belgian Population and STI Clinic Attendees. International Journal of Infectious Diseases 2022; 116: S2.
42
Kenyon C, Vanbaelen T, Van Dijck C. Recent insights suggest the need for the STI field to embrace a more eco-social conceptual framework: A viewpoint. Int J STD AIDS 2022; 33: 404–15.
43
Laumen JGE, Abdellati S, Manoharan-Basil SS, et al. Screening of Anorectal and Oropharyngeal Samples Fails to Detect Bacteriophages Infecting Neisseria gonorrhoeae. Antibiotics (Basel) 2022; 11. DOI:10.3390/antibiotics11020268.
44
Van Dijck C, Tsoumanis A, De Hondt A, et al. Chlorhexidine Mouthwash Fails to Eradicate Oropharyngeal Gonorrhea in a Clinical Pilot Trial (MoNg). Sex Transm Dis 2022; 49: e38–41.
45
Van Dijck C, De Baetselier I, Cuylaerts V, et al. Gonococcal bacterial load in PrEP users with Mycoplasma genitalium coinfection. Int J STD AIDS 2022; 33: 129–35.
46
Laumen JGE, Abdellati S, Van Dijck C, et al. A Novel Method to Assess Antimicrobial Susceptibility in Commensal Oropharyngeal Neisseria-A Pilot Study. Antibiotics (Basel) 2022; 11. DOI:10.3390/antibiotics11010100.
47
Laumen JGE, Van Dijck C, Abdellati S, et al. Antimicrobial susceptibility of commensal Neisseria in a general population and men who have sex with men in Belgium. Sci Rep 2022; 12: 9.
48
González N, Elise Laumen JG, Abdellati S, et al. Pre-exposure to azithromycin enhances gonococcal resilience to subsequent ciprofloxacin exposure: an in vitro study. F1000Res 2022; 11: 1464.
49
de Block T, González N, Abdellati S, et al. Successful Intra- but Not Inter-species Recombination of msr(D) in Neisseria subflava. Front Microbiol 2022; 13: 855482.
50
Vanbaelen T, Van Dijck C, De Baetselier I, et al. Screening for STIs is one of the main drivers of macrolide consumption in PrEP users. Int J STD AIDS 2021; 32: 1183–4.
51
Kenyon C, Manoharan-Basil SS, Van Dijck C. Is There a Resistance Threshold for Macrolide Consumption? Positive Evidence from an Ecological Analysis of Resistance Data from Streptococcus pneumoniae, Treponema pallidum, and Mycoplasma genitalium. Microb Drug Resist 2021; 27: 1079–86.
52
Rotsaert A, Reyniers T, Van Dijck C, Vuylsteke B, Kenyon C. Proposing an antibacterial mouthwash to prevent gonorrhoea is not sexy. Lancet Infect Dis 2021; 21: 909.
53
Laumen JGE, Manoharan-Basil SS, Verhoeven E, et al. Molecular pathways to high-level azithromycin resistance in Neisseria gonorrhoeae. J Antimicrob Chemother 2021; 76: 1752–8.
54
Van Dijck C, Tsoumanis A, Rotsaert A, et al. Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial. Lancet Infect Dis 2021; 21: 657–67.
55
de Block T, Laumen JGE, Van Dijck C, et al. WGS of Commensal Neisseria Reveals Acquisition of a New Ribosomal Protection Protein (MsrD) as a Possible Explanation for High Level Azithromycin Resistance in Belgium. Pathogens 2021; 10. DOI:10.3390/pathogens10030384.
56
Laumen JGE, Van Dijck C, Abdellati S, et al. Markedly Reduced Azithromycin and Ceftriaxone Susceptibility in Commensal Neisseria Species in Clinical Samples From Belgian Men Who Have Sex With Men. Clin Infect Dis 2021; 72: 363–4.
57
Van Dijck C, Vanbaelen T, Laumen J, Kenyon C. P316 Could number of partners be a risk for antimicrobial resistance? Higher macrolide consumption amongst a core group of PrEP users. Sexually Transmitted Infections 2021; 97: A142.1-A142.
58
Manoharan-Basil SS, Laumen JGE, Van Dijck C, De Block T, De Baetselier I, Kenyon C. Evidence of Horizontal Gene Transfer of 50S Ribosomal Genes rplB, rplD, and rplY in Neisseria gonorrhoeae. Front Microbiol 2021; 12: 683901.
59
Laumen JGE, Van Dijck C, Manoharan-Basil SS, et al. Sub-Inhibitory Concentrations of Chlorhexidine Induce Resistance to Chlorhexidine and Decrease Antibiotic Susceptibility in Neisseria gonorrhoeae. Front Microbiol 2021; 12: 776909.
60
Kenyon C, Laumen J, Van Dijck C, et al. Gonorrhoea treatment combined with population-level general cephalosporin and quinolone consumption may select for Neisseria gonorrhoeae antimicrobial resistance at the levels of NG-MAST genogroup: An ecological study in Europe. J Glob Antimicrob Resist 2020; 23: 377–84.
61
Van Dijck C, Laumen J, Zlotorzynska M, Manoharan-Basil SS, Kenyon C. Association between STI screening intensity in men who have sex with men and gonococcal susceptibility in 21 States in the USA: an ecological study. Sex

Transm Infect 2020; 96: 537–40.
62
Kenyon C, Manoharan-Basil SS, Van Dijck C. Gonococcal resistance can be viewed productively as part of a syndemic of antimicrobial resistance: an ecological analysis of 30 European countries. Antimicrob Resist Infect Control 2020; 9: 97.
63
Van Dijck C, Laumen JGE, Manoharan-Basil SS, Kenyon C. Commensal Neisseria Are Shared between Sexual Partners: Implications for Gonococcal and Meningococcal Antimicrobial Resistance. Pathogens 2020; 9. DOI:10.3390/pathogens9030228.
64
Kenyon C, Van Dijck C, Florence E. Facing increased sexually transmitted infection incidence in HIV preexposure prophylaxis cohorts: what are the underlying determinants and what can be done? Curr Opin Infect Dis 2020; 33: 51–8.
65
Kenyon C, Laumen J, Van Dijck C. Could Intensive Screening for Gonorrhea/Chlamydia in Preexposure Prophylaxis Cohorts Select for Resistance? Historical Lessons From a Mass Treatment Campaign in Greenland. Sex Transm Dis 2020; 47: 24–7.
66
Kenyon C, Laumen J, Van Den Bossche D, Van Dijck C. Where have all the susceptible gonococci gone? A historical review of changes in MIC distribution over the past 75 years. BMC Infect Dis 2019; 19: 1085.
67
Van Dijck C, Cuylaerts V, Sollie P, et al. The development of mouthwashes without anti-gonococcal activity for controlled clinical trials: an in vitro study. F1000Res 2019; 8: 1620.
68
Van Dijck C, Vlieghe E, Cox JA. Antibiotic stewardship interventions in hospitals in low-and middle-income countries: a systematic review. Bull World Health Organ 2018; 96: 266–80.
69
Van Dijck C, Van Esbroeck M, Rutsaert R. A 54-year-old Philippine sailor with fever and jaundice. Acta Clin Belg 2016; 71: 319–22.
70
Sieliwonczyk E, Vlieghe E, Van Dijck C. Headache in a patient with polycythemia. Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine 2016.
71
Van Dijck C, Coremans P, De Meester J. Recurrent hypoglycaemia in a non-diabetic patient. Acta Clinica Belgica 2013; 68: 459.
72
Francque S, Laleman W, Verbeke L, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest 2012; 92: 1428–39.
73
Francque S, Laleman W, Verbeke L, et al. 1235 Severe Steatosis Is Associated With a Haemodynamically Significant Increase in Intrahepatic Resistance in Association With Both Endothelial Dysfunction and Morphological Alterations in a Rat Model. Journal of Hepatology 2012; 56: S489–90.
74
Francque S, Laleman W, Verbeke L, et al. SEVERE STEATOSIS IS ASSOCIATED WITH A HAEMODYNAMICALLY SIGNIFICANT INCREASE IN INTRAHEPATIC RESISTANCE IN ASSOCIATION WITH BOTH ENDOTHELIAL DYSFUNCTION AND MORPHOLOGICAL ALTERATIONS IN A RAT MODEL. Journal Of Hepatology 2012; 56: S489–90.

Projects

2026 - present: Investigator Academic RCT "A Phase III Randomised, Open Label Trial of an Intradermal or Subcutaneous booster dose of MVA-BN Vaccine to Investigate MPXV Immunogenicity and Safety for Protection Against Mpox in an Intradermally or Subcutaneously Primary Vaccinated Population – an adaptive protocol and a Non-Randomised Trial of a Subcutaneous Booster Dose for Subcutaneously Primary Vaccinated" (MPOX BOOSTER TRIAL)

2024 - present: Principal Investigator Academic Cohort study of individuals infected with mpox and/or vaccinated with MVA-BN (MPOX-COHORT & POQS-FU-PLUS)

2024 - present: Coordinator of FWO Junior Research Project "Guarding Against the Reintroduction of monkeypox virus: Assessing Vulnerability and Mitigation Strategies in the Belgian MSM Population" (G069725N)

2024 - 2025: Study Coordinator Academic Cohort study Mapping the burden of ocular complications of mpox in DRC (MPOX-EYE STUDY)

2024 - 2025: Sub-Investigator Academic RCT "European randomised clinical trial on mPOX Infection" (EPOXI)

2019 – 2020: Investigator Academic RCT "Preventing Resistance in Gonorrhoea Study" (PReGo)

Memberships

2017 - present european society of clinical microbiology and infectious diseases (escmid): membership

2017 - present belgian society of infectious diseases and clinical microbiology (bvikm): membership

2023 - present FWO postdoctoral fellowship 2023 – 2026 (12B1M24N)

Title: "Mpox, a tale of two epidemics: unraveling differences in disease expression and transmission between Europe and Central Africa"

Other Relevant Information